1.
CBP per cumulative year for daratumumab and pembrolizumab per vial.
2.
3.
4.
5.
CBP per cumulative indication for daratumumab and pembrolizumab per vial.
Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.
Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.
Implementation of indication-based pricing (10 th scenario) for daratumumab and pembrolizumab.
Input parameters for the base-case analysis.
Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.
Adsorbate-Dependent Electronic Structure Descriptors for Machine Learning-Driven Binding Energy Predictions in Diverse Single Atom Alloys: A Reductionist Approach